Continuous infusion of macrophage inflammatory protein MIP-1α enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide

British Journal of Cancer

Volumn 75, Issue 12, 1997, Pages 1715-1720

  Marshall, E ^a,c   Woolford, L B ^b   Lord, B I ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

BE 10010; Granulocyte colony stimulating factor; MIP 1 ; Mobilization; Myeloprotection

Indexed keywords

ANTIMITOTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL CYCLE S PHASE; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMING UNIT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030957704     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.294     Document Type: Article

References (20)

1. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DT, Wolpe SD and Pragnell IB (1992) Demonstration of stem cell inhibition and myeloproliferative effects of SC1/rhMIP1α in vivo. Blood 79: 2221-2225
2. Graham GJ, Wright EG, Hewick R, Wolpe SD, Wilkie NM, Donaldson D, Lorimore S and Pragnell IB (1990) Identification and characterisation of an inhibitor of haemopoietic stem cell proliferation. Nature 344: 442-444
3. Hunter MG, Bawden L, Brotherton S, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM and Lewis PJ (1995) BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood 86: 4400-4408
4. Jagel MA and Hugli TE (1992) Neutrophil chemotactic factors promote leucocytosis. J Immunol 148: 1119-1128
5. Keller JR, Bartelmez SH, Sitnicka R, Ruscetti FW, Ortiz M, Gooya JM and Jacobsen SEN (1994) Distinct and overlapping direct effects of macrophage inflammatory protein-1α and transforming growth factor β on haematopoietic progenitor/stem cell growth. Blood 84: 2175-2181
6. Laterveer L, Lindley IJD, Hamilton MS, Willsemze R and Fibbe WE (1995) Interleukin-8 induces rapid mobilisation of haematopoietic stem cells radioprotective capacity and long term myelolymphoid repopulating ability. Blood 85: 2269-2275
7. Lord BI (1993) In vivo assays for multipotential and marrow repopulating cells. In Haemopoiesis: A Practical Approach, Testa NG and Molineux G. (eds), p. 1. 1RL/Oxford University: Oxford, UK
8. Lord BI (1995) MIP1α increases the self renewal capacity of the haemopoietic spleen colony forming cells following hydroxyurea treatment in vivo. Growth Factors 12: 145-149
9. Lord BI, Mori KJ, Wright EG, and Lajtha LG (1976) An inhibitor of stem cell proliferation in normal bone marrow. Br J Haematol 34: 441-445
10. Lord BI, Dexter TM, Clements JM, Hunter MG and Gearing AJH (1992) Macrophage inflammatory protein protects multipotent haemopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 79: 2605-2609
11. Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG and Edwards RM (1995) Mobilisation of early haematopoietic progenitor cells with BB10010: a genetically engineered variant of human macrophage inflammatory protein -1α. Blood 85: 3412-3415
12. Lord BI, Marshall E and Woolford L (1996) Protection, in vivo, by BB10010 (MIP1α) against repeated treatments with non-cycle active cytotoxic agents: sub-lethal irradiated. Br J Cancer 74: 1017-1022
13. Molineux G, Xu C, Hendry J and Testa NG (1986) A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide. Cancer Chemother Pharmacol 18: 11-16
14. Oppenheim JJ, Zachariae COC, Mukaida N and Matsushima K (1991) Properties of the novel proinflammatory intercrine cytokine family. Annu Rev Immunol 9: 617-648
15. Passos-Coelho JL, Braine HG, Davis JM, Huelskamp AM, Schepers KG, Ohly K, Clarke B, Wright SK, Noga SJ, Davidson NE and Kennedy MJ (1995) Predictive factors for peripheral blood collections using a single large volume leukapheresis after cyclophosphamide and GM-CSF. J Clin Oncol 13: 705-714
16. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, and Dahinden CA (1992) RANTES and macrophage inflammatory protein-1α induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 176: 1489-1495
17. Schall TJ, Bacon K, Camp RD, Kaspari JW and Goeddel DV (1993) Human macrophage inflammatory protein -1α and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 177: 1821-1826
18. Wang JM, Sherry B, Fivash MJ, Kelvin DJ and Oppenheim JJ (1993) Human recombinant macrophage inflammatory protein-1α and -beta and monocyte chemotactic and activating factor utilise common and unique receptors on human monotytes. J Immunol 150: 3022-3029
19. Wolpe SD and Cerami A (1989) Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J 3: 2565-2573
20. Wolpe SD, Davatelis SG, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathan LF, Lowry SF and Cerami A (1988) Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 167: 570-581